Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

Investors are expected to be cautious with DIVISLAB, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 5.69600
forwardPE 54.03482
debtToEquity 0.58400
earningsGrowth 0.35300
revenueGrowth 0.16100
grossMargins 0.60794
operatingMargins 0.28545
trailingEps 93.70000
forwardEps 56.30000

DIVISLAB's current ratio being 5.696 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that DIVISLAB can meet its financial obligations with ease.
DIVISLAB's forward PE is too high, signaling potential overvaluation. This could cap future price increases and trigger a correction. Investors should carefully analyze this metric along with other fundamental indicators before making investment decisions.
Divi's Laboratories Limited's positive growth in earnings and revenue suggests the company is on track to expand its business. These indicators highlight a healthy financial performance, with Divi's Laboratories Limited expected to increase its market presence and profitability.
DIVISLAB's positive gross and operating margins indicate strong financial performance. These margins show that the company is profitable and efficient in its operations, with effective cost control contributing to its overall financial success.
With forward EPS less than trailing EPS, DIVISLAB is expected to see reduced earnings. This suggests the company may face profitability challenges in the current financial year compared to the previous one.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

DIVISLAB's price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in DIVISLAB's ability to achieve future growth.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


12 transactions were made to sell DIVISLAB shares, with market price of 6291.595865885417.There were 2 purchases of DIVISLAB stock, with market price of 5854.875.Divi's Laboratories Limited's current price levels have seen more sells, possibly signaling bearish sentiment. If this trend remains unchanged, the stock could experience further declines as more investors opt to sell rather than hold their positions.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


The analysts' mixed ratings for DIVISLAB indicate no clear guidance on whether to buy or sell. Investors may need to explore other data points or wait for more concrete market signals before taking any decisive action regarding DIVISLAB.